Skip to main content
Equibles
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Metrics

Track RIGL — free

Use RIGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RIGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$41.32 +1.67 (+4.20%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$746.61M
Shares
18.83M
Volume · Nov 9 44.78K Avg daily vol (3M) 260.25K

RIGL metrics

99 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$39.65
Market cap
$746.61M

Price action

23 metrics
Price change (1W)
-22.7%
Price change (30D)
-19.2%
Price change (3M)
-1.3%
Price change (6M)
+52.3%
Price change (YTD)
-7.4%
Price change (1Y)
+9.8%
Trailing year
Price change (5Y)
—
52-week high
$51.45
52-week low
$25.44
Change from 52-week high
-22.9%
Change from 52-week low
+55.9%
Annualized volatility
55.4%
Annualized volatility (3M)
51.3%
Implied volatility (30D)
70.9%
IV rank (1Y)
33.4
IV percentile (1Y)
55.6
Beta
1.0
RSI (14D)
30.1
Price vs SMA 50
-17.0%
Price vs SMA 200
+6.0%
Avg volume (3M)
260,248
Relative volume
2.9
Average dollar volume
$12.05M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
18.83M

Valuation

12 metrics
P / E (TTM)
2.5
Trailing earnings · reciprocal yield 40.6%
PEG ratio
—
EV / revenue
2.2×
reciprocal yield 44.7%
EV / EBITDA
8.1×
reciprocal yield 12.3%
EV / EBIT
8.5×
reciprocal yield 11.7%
P / sales
2.6×
reciprocal yield 38.6%
P / book
1.7
reciprocal yield 59.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
8.3
reciprocal yield 12.0%
Earnings yield
41.1%

Historical valuation

8 metrics
P / E historical average (3Y)
13.2×
reciprocal yield 7.6%
P / E historical average (5Y)
13.2×
reciprocal yield 7.6%
EV / revenue historical average (3Y)
1.8×
reciprocal yield 56.9%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 53.7%
EV / EBIT historical average (3Y)
9.2×
reciprocal yield 10.8%
EV / EBIT historical average (5Y)
9.2×
reciprocal yield 10.8%
EV / EBITDA historical average (3Y)
8.2×
reciprocal yield 12.2%
EV / EBITDA historical average (5Y)
8.2×
reciprocal yield 12.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
89.6%
Operating margin
26.3%
Trailing 12 months
Net margin
106.6%
Gross profit (TTM)
$258.34M
Operating profit (TTM)
$75.73M
Net income (TTM)
$307.19M
Trailing 12 months
Diluted EPS (TTM)
$16.08
FCF margin
—
Effective tax rate
-307.6%

Per share

11 metrics
Revenue per diluted share (TTM)
$14.48
Gross profit per diluted share (TTM)
$12.99
Operating profit per diluted share (TTM)
$3.81
EBITDA per diluted share (TTM)
$4.00
Net income per diluted share (TTM)
$15.47
Operating cash flow per diluted share (TTM)
$4.50
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$2.74
Stock compensation per diluted share (TTM)
$0.90
Book value per share
$21.38

Growth

11 metrics
Revenue growth YoY
+16.5%
Year over year
Net income growth YoY
-52.7%
Revenue (TTM)
$288.21M
Trailing 12 months
EPS growth YoY
-55.5%
Shares change YoY
+6.7%
Year over year · more shares
Revenue CAGR (3Y)
+34.8%
Revenue CAGR (5Y)
+22.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
69.0%
Return on assets
58.6%
Debt / equity
0.1
Current ratio
2.4
EBITDA (TTM)
$79.57M
Free cash flow (TTM)
—
Quick ratio
2.2
Interest coverage
18.2
Net debt / EBITDA
-1.3
Return on invested capital
—
Trailing 12 months
Net cash
$101.68M
Latest balance sheet
Cash & equivalents
$46.65M
Total assets
$523.88M
Total debt
$45.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$89.92M
Capital expenditures (TTM)
—
R&D (TTM)
$54.59M
SG&A (TTM)
$128.01M
Stock compensation (TTM)
$17.90M
R&D / revenue
18.9%
Stock compensation / revenue
6.2%

Ownership (13F)

9 metrics
13F filers
158
13F filer change QoQ
-1
Institutional ownership
87.9%
Conviction holders (share of 13F filers)
1.3%
Crowding (high-turnover and private-fund holders)
37.8%
Private-fund adviser ownership
24.7%
Active holders' share change QoQ
+5.4%
Holder tenure
11.3
Price vs estimated holder cost
+29.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
19.3%

Short interest

3 metrics
Short interest
14.5%
Latest settlement · 12.8 days to cover
Days to cover
12.8d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1034842 CUSIP 766559702 13F (30d) 79 filings 60 filers Visit website Investor relations